Thymosin Alpha-1 vs Vilon
Comparison of Thymosin Alpha-1 (Moderate evidence) and Vilon (Low evidence).
Last updated: February 12, 2026
Thymosin Alpha-1
Vilon
Overview
Thymosin Alpha-1 and Vilon are both studied in the peptide research space.
Thymosin Alpha-1: A 28-amino acid immunomodulatory peptide approved in over 35 countries including China and Italy for hepatitis B/C, cancer adjuvant therapy, and immunodeficiency.
Vilon: A synthetic dipeptide (Lys-Glu) developed by Russian scientist Vladimir Khavinson as part of the peptide bioregulation framework.
Evidence Comparison
| Aspect | Thymosin Alpha-1 | Vilon |
|---|---|---|
| Evidence Level | Moderate | Low |
| Human Studies | 28 | 2 |
| Preclinical Studies | 14 | 10 |
| Total Sources | 42 | 15 |
Key Differences
| Aspect | Thymosin Alpha-1 | Vilon |
|---|---|---|
| Category | Immune | Immune |
| Evidence Strength | Moderate | Low |
| Total Sources | 42 | 15 |
| Human Studies | 28 | 2 |
Summary
- Thymosin Alpha-1: Moderate evidence with 42 total sources (28 human)
- Vilon: Low evidence with 15 total sources (2 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.